Analysts Expect Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Will Announce Quarterly Sales of $40,000.00

Wall Street analysts predict that Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) will announce $40,000.00 in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Aurinia Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $10,000.00 and the highest estimate coming in at $100,000.00. Aurinia Pharmaceuticals reported sales of $30,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 33.3%. The company is expected to announce its next earnings results on Tuesday, March 17th.

According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full-year sales of $340,000.00 for the current financial year, with estimates ranging from $300,000.00 to $400,000.00. For the next financial year, analysts anticipate that the firm will post sales of $140,000.00, with estimates ranging from $100,000.00 to $200,000.00. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, November 14th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The firm had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.79% and a negative net margin of 19,483.96%.

Several brokerages have recently issued reports on AUPH. Citigroup assumed coverage on shares of Aurinia Pharmaceuticals in a research report on Monday, September 9th. They set an “outperform” rating and a $14.00 target price on the stock. HC Wainwright set a $25.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 1st. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, November 28th. Bloom Burton reaffirmed a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 2nd. Finally, BidaskClub upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $18.46.

A number of institutional investors have recently added to or reduced their stakes in AUPH. Swiss National Bank boosted its holdings in Aurinia Pharmaceuticals by 14.0% in the second quarter. Swiss National Bank now owns 111,800 shares of the biotechnology company’s stock valued at $738,000 after acquiring an additional 13,700 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Aurinia Pharmaceuticals by 35.5% during the 2nd quarter. Wells Fargo & Company MN now owns 77,993 shares of the biotechnology company’s stock valued at $513,000 after purchasing an additional 20,432 shares in the last quarter. Toronto Dominion Bank raised its stake in Aurinia Pharmaceuticals by 26.3% during the 2nd quarter. Toronto Dominion Bank now owns 12,355 shares of the biotechnology company’s stock worth $81,000 after buying an additional 2,575 shares during the period. BlackRock Inc. raised its stake in shares of Aurinia Pharmaceuticals by 3.1% in the second quarter. BlackRock Inc. now owns 921,425 shares of the biotechnology company’s stock worth $6,063,000 after purchasing an additional 28,129 shares during the last quarter. Finally, Vivo Capital LLC increased its position in shares of Aurinia Pharmaceuticals by 57.7% during the second quarter. Vivo Capital LLC now owns 1,913,623 shares of the biotechnology company’s stock valued at $12,592,000 after acquiring an additional 700,333 shares during the last quarter. Hedge funds and other institutional investors own 32.06% of the company’s stock.

Shares of AUPH traded up $1.92 during midday trading on Friday, hitting $17.70. 19,389,262 shares of the company traded hands, compared to its average volume of 1,267,964. The firm has a 50 day moving average of $6.99 and a 200-day moving average of $6.22. Aurinia Pharmaceuticals has a 52 week low of $3.52 and a 52 week high of $18.49. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -23.29 and a beta of 1.25.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: What is a growth and income fund?

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.